| NCT ID | NCT04844060 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2010-02 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2010-02 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cognitive neurodegenerative diseases are a major public health issue. At present, the diagnosis of certainty is still based on anatomopathological analyses. Even if the diagnostic tools available to clinicians have made it possible to improve probabilistic diagnosis during the patient's lifetime, there are still too many diagnostic errors and sub-diagnostic in this field. The arrival of biomarkers has made it possible to reduce these diagnostic errors, which were of the order of 25 to 30%. This high error rate is due to different parameters. These diseases are numerous and often present common symptoms due to the fact that common brain structures are affected. These diseases evolve progressively over several years and their early diagnosis, when the symptoms are discrete, makes them even more difficult to diagnose at this stage. In addition, co-morbidities are common in the elderly, further complicating the diagnosis of these diseases. At present, the only cerebrospinal fluid (CSF) biomarkers that are routinely used for the biological diagnosis of neurodegenerative cognitive pathologies are those specific to Alzheimer's disease: Aβ42, Aβ40, Tau-total and Phospho-Tau. These biomarkers represent an almost indispensable tool in the diagnosis of dementia. It is therefore important to determine whether Alzheimer's biomarkers can be disrupted in other neurodegenerative cognitive pathologies, but also to find biomarkers specific to these different pathologies by facilitating the implementation of clinical studies which will thus make it possible to improve their diagnosis.
Eligibility Criteria
Inclusion Criteria: * Patients with lumbar puncture (LP) * Patients with accurate clinical diagnosis Exclusion Criteria: * Patients who do not have a lumbar puncture * Patients for whom no accurate diagnostic information is available
Contact & Investigator
Frédéric BLANC, MD/PhD
PRINCIPAL INVESTIGATOR
Hôpitaux Universitaires de Strasbourg
Frequently Asked Questions
Who can join the NCT04844060 clinical trial?
This trial is open to participants of all sexes, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04844060 currently recruiting?
Yes, NCT04844060 is actively recruiting participants. Contact the research team at frederic.blanc@unistra.fr for enrollment information.
Where is the NCT04844060 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT04844060 clinical trial?
NCT04844060 is sponsored by University Hospital, Strasbourg, France. The principal investigator is Frédéric BLANC, MD/PhD at Hôpitaux Universitaires de Strasbourg. The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.